Sterling Investment Counsel LLC Purchases 1,120 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sterling Investment Counsel LLC lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 108.3% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,154 shares of the medical research company's stock after buying an additional 1,120 shares during the quarter. Sterling Investment Counsel LLC's holdings in Thermo Fisher Scientific were worth $1,072,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Semus Wealth Partners LLC grew its stake in shares of Thermo Fisher Scientific by 4.0% in the 4th quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after buying an additional 18 shares during the last quarter. Revolve Wealth Partners LLC boosted its holdings in Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares in the last quarter. Cassaday & Co Wealth Management LLC grew its stake in shares of Thermo Fisher Scientific by 0.9% in the fourth quarter. Cassaday & Co Wealth Management LLC now owns 2,286 shares of the medical research company's stock worth $1,189,000 after acquiring an additional 20 shares during the last quarter. Callan Capital LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Callan Capital LLC now owns 773 shares of the medical research company's stock valued at $402,000 after acquiring an additional 20 shares in the last quarter. Finally, One Charles Private Wealth Services LLC boosted its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after purchasing an additional 20 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE TMO traded up $2.28 on Thursday, hitting $392.54. 2,883,201 shares of the company traded hands, compared to its average volume of 1,944,785. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. The business's 50 day moving average price is $414.12 and its 200-day moving average price is $489.73. The company has a market capitalization of $148.18 billion, a price-to-earnings ratio of 23.02, a P/E/G ratio of 2.06 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The company had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the company posted $5.11 EPS. The firm's revenue was up .2% on a year-over-year basis. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.44%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is currently 10.09%.

Analyst Ratings Changes

Several research analysts have issued reports on TMO shares. Robert W. Baird decreased their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Stifel Nicolaus decreased their price objective on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating for the company in a report on Thursday, April 24th. Citigroup cut their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Finally, Evercore ISI dropped their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.